Treggiari-Venzi M M, Suter P M, Romand J A
Department of Anesthesia, Pharmacology, and Surgical Intensive Care, University Hospital, Geneva, Switzerland.
Neurosurgery. 2001 Feb;48(2):249-61; discussion 261-2. doi: 10.1097/00006123-200102000-00001.
Cerebral vasospasm remains a devastating medical complication of aneurysmal subarachnoid hemorrhage (SAH). It is associated with high morbidity and mortality rates, even after the aneurysm has been secured surgically or radiologically. A great deal of experimental and clinical research has been conducted in an effort to find ways to prevent this complication. The literature includes extensive coverage of in vivo animal model studies of SAH and vasospasm. These experimental studies have contributed to tremendous advances in the understanding of the mechanisms leading to cerebral vasospasm. Most of the experimental settings, however, have demonstrated varying levels of ability to predict accurately what occurs in human SAH. Therefore, although animal models have been developed to test new therapies, most of the treatment effects have been shown to be less compelling when trials have been conducted in clinical settings. The interpretation of current literature is complicated further by the imprecise estimation of the incidence of cerebral vasospasm, which is due to various degrees of clinical expression, ranging from the absence of symptoms in the presence of increased blood flow velocities at transcranial Doppler or vessel diameter reduction at angiography to neurological manifestations of severe ischemic deficits. In addition, a change over time in the incidence pattern of human SAH and vasospasm, possibly related to improved surgical techniques and overall patient management, may have occurred. This topic review collects the relevant literature on clinical trials investigating prophylactic therapies for cerebral vasospasm in patients with aneurysmal SAH and emphasizes the need for large clinical trials to confirm the results derived from clinical experience. In addition, it points out some experimental therapies that may hold promise in future clinical trials to prevent the occurrence of vasospasm.
脑血管痉挛仍然是动脉瘤性蛛网膜下腔出血(SAH)的一种极具破坏性的医学并发症。即使动脉瘤已通过手术或放射学方法得到妥善处理,它仍与高发病率和死亡率相关。为了找到预防这种并发症的方法,人们进行了大量的实验和临床研究。文献中广泛涵盖了SAH和血管痉挛的体内动物模型研究。这些实验研究在理解导致脑血管痉挛的机制方面取得了巨大进展。然而,大多数实验设置在准确预测人类SAH中发生的情况方面,表现出不同程度的能力。因此,尽管已经开发了动物模型来测试新疗法,但在临床环境中进行试验时,大多数治疗效果并不那么令人信服。由于临床症状表现程度各异,从经颅多普勒检测到血流速度增加或血管造影显示血管直径缩小时无症状,到严重缺血性缺陷的神经学表现,脑血管痉挛发病率的不精确估计进一步使当前文献的解读变得复杂。此外,人类SAH和血管痉挛的发病率模式可能随时间发生了变化,这可能与手术技术的改进和整体患者管理有关。本专题综述收集了关于动脉瘤性SAH患者脑血管痉挛预防性治疗的临床试验相关文献,并强调需要进行大型临床试验以证实从临床经验中得出的结果。此外,它还指出了一些在未来临床试验中可能有望预防血管痉挛发生的实验性疗法。